Dr Jens Hillengass speaks to ecancer about evolving concepts in the diagnosis and staging of multiple myeloma.

He says multiple myeloma is the second most common type of blood cancer, occurring when plasma cells; a type of white blood cell, multiply out of control. Abnormal plasma cells, called myeloma cells, collect mostly in bone marrow and can cause bones to weaken. He speaks about the new diagnostic criteria that has been introduced to define treatment-necessitating myeloma, or myeloma that is advanced enough or serious enough to require some therapeutic intervention.

Dr Hillengass explains some of the new treatment techniques that can be used to treat these patients and winds it up by talking about the future of multiple myeloma treatment looks like.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.